title: Radiolabeled antibodies directed at CD45 for conditioning prior to allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome.
abstract: While allogeneic hematopoietic cell transplantation (HCT) may offer the best chance of cure for patients suffering from aggressive hematological malignancies such as acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome, successful outcomes for the subgroup of patients with high-risk disease remain disappointing and lag behind those of lower-risk patients. Because relatively high rates of relapse are an important contributor to these poor outcomes, efforts have explored approaches to increase the cytotoxic effects of treatment. Relapse rates have been shown to improve with the addition of increased doses of total body irradiation (TBI) and/or the introduction of additional chemotherapy to a HCT conditioning regimen. However, the increase in TBI dose and/or additional chemotherapy has also been associated with a significant increase in life-threatening toxicities, resulting in no change in overall survival. Radioimmunotherapy (RIT) has been employed as an adjunct to HCT where targeted delivery of radiation may allow for further escalation of therapy to reduce relapse with minimal toxicity. In this review we describe these efforts, including the benefits of escalating the dose of radiation to sites of hematologic disease prior to HCT, the various cellular targets for antibody-mediated delivery of radiation, as well as the rationale for incorporation of various radionuclides such as alpha emitters and beta emitters into the preparative regimen prior to HCT. Lastly, newer novel approaches such as pretargeted RIT (PRIT) are described as a method to further increase delivery of targeted radiation to hematological tissues while sparing noninvolved organs.
authors.forename: Johnnie J
authors.initials: JJ
authors.lastname: Orozco
authors.forename: Jill
authors.initials: J
authors.lastname: Zeller
authors.forename: John M
authors.initials: JM
authors.lastname: Pagel
keywords: CD45; antibodies; hematopoietic cell transplantation; radioimmunotherapy
references.citation: Blood. 2009 Dec 24;114(27):5444-53
references.pmid: 19786617
references.citation: Blood. 1990 Nov 1;76(9):1867-71
references.pmid: 2224134
references.citation: Blood. 2006 Mar 1;107(5):2184-91
references.pmid: 16254140
references.citation: Blood. 1991 Oct 1;78(7):1864-74
references.pmid: 1832994
references.citation: Cancer Res. 2006 Apr 1;66(7):3884-92
references.pmid: 16585217
references.citation: Leuk Res. 1997 Feb;21(2):133-8
references.pmid: 9112430
references.citation: Blood. 2008 Feb 15;111(4):2261-8
references.pmid: 18042793
references.citation: Blood. 1991 Apr 15;77(8):1660-5
references.pmid: 2015394
references.citation: Am J Clin Pathol. 1983 May;79(5):546-52
references.pmid: 6188365
references.citation: Cancer Res. 2009 Jan 1;69(1):185-92
references.pmid: 19118002
references.citation: Blood. 2001 Aug 1;98(3):565-72
references.pmid: 11468151
references.citation: Transplantation. 2004 Aug 15;78(3):352-9
references.pmid: 15316362
references.citation: Cancer Biother Radiopharm. 2000 Feb;15(1):15-29
references.pmid: 10740649
references.citation: Expert Opin Biol Ther. 2004 Jan;4(1):95-105
references.pmid: 14680472
references.citation: Cancer. 1997 Dec 1;80(11 Suppl):2205-9
references.pmid: 9395035
references.citation: Br J Haematol. 2003 May;121(3):458-61
references.pmid: 12716368
references.citation: J Nucl Med. 2006 Aug;47(8):1335-41
references.pmid: 16883014
references.citation: J Clin Oncol. 1991 Mar;9(3):478-90
references.pmid: 1999719
references.citation: Cancer Res. 2009 Mar 15;69(6):2408-15
references.pmid: 19244101
references.citation: Curr Oncol Rep. 2005 Sep;7(5):339-46
references.pmid: 16091194
references.citation: J Clin Oncol. 2010 Jun 10;28(17):2859-67
references.pmid: 20439626
references.citation: Br J Haematol. 2005 Aug;130(4):604-13
references.pmid: 16098076
references.citation: Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):787-94
references.pmid: 15701869
references.citation: Clin Cancer Res. 2010 Nov 1;16(21):5303-11
references.pmid: 20858843
references.citation: Semin Nucl Med. 2010 May;40(3):190-203
references.pmid: 20350628
references.citation: N Engl J Med. 1993 Oct 21;329(17):1219-24
references.pmid: 7692295
references.citation: Blood. 1998 Aug 15;92(4):1455-6
references.pmid: 9694737
references.citation: J Exp Med. 1980 Oct 1;152(4):842-52
references.pmid: 6968338
references.citation: Blood. 1999 Aug 15;94(4):1237-47
references.pmid: 10438711
references.citation: J Clin Oncol. 1998 Mar;16(3):872-81
references.pmid: 9508168
references.citation: Blood. 1994 Mar 1;83(5):1390-7
references.pmid: 8118040
references.citation: Blood. 2002 Jul 1;100(1):318-26
references.pmid: 12070043
references.citation: Transplantation. 1992 Nov;54(5):829-33
references.pmid: 1440849
references.citation: Blood. 2011 Jul 21;118(3):703-11
references.pmid: 21613259